- Home
- WYY vs BOLD Comparison
WYY vs BOLD Comparison
Compare WYY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- BOLD
- Stock Information
- Founded
- WYY 1991
- BOLD 2018
- Country
- WYY United States
- BOLD United States
- Employees
- WYY N/A
- BOLD N/A
- Industry
- WYY EDP Services
- BOLD
- Sector
- WYY Technology
- BOLD
- Exchange
- WYY Nasdaq
- BOLD Nasdaq
- Market Cap
- WYY 33.6M
- BOLD 24.4M
- IPO Year
- WYY 1998
- BOLD 2024
- Fundamental
- Price
- WYY $2.96
- BOLD $1.19
- Analyst Decision
- WYY Strong Buy
- BOLD Buy
- Analyst Count
- WYY 1
- BOLD 3
- Target Price
- WYY $7.00
- BOLD $4.00
- AVG Volume (30 Days)
- WYY 58.6K
- BOLD 105.1K
- Earning Date
- WYY 08-14-2025
- BOLD 08-11-2025
- Dividend Yield
- WYY N/A
- BOLD N/A
- EPS Growth
- WYY N/A
- BOLD N/A
- EPS
- WYY N/A
- BOLD N/A
- Revenue
- WYY $142,582,209.00
- BOLD N/A
- Revenue This Year
- WYY $9.05
- BOLD N/A
- Revenue Next Year
- WYY $12.24
- BOLD N/A
- P/E Ratio
- WYY N/A
- BOLD N/A
- Revenue Growth
- WYY 24.03
- BOLD N/A
- 52 Week Low
- WYY $2.19
- BOLD $1.00
- 52 Week High
- WYY $6.25
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- WYY 41.39
- BOLD N/A
- Support Level
- WYY $2.99
- BOLD N/A
- Resistance Level
- WYY $3.23
- BOLD N/A
- Average True Range (ATR)
- WYY 0.19
- BOLD 0.00
- MACD
- WYY -0.01
- BOLD 0.00
- Stochastic Oscillator
- WYY 27.59
- BOLD 0.00
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.